Survival in Primary Pulmonary Hypertension
Top Cited Papers
- 17 September 2002
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 106 (12), 1477-1482
- https://doi.org/10.1161/01.cir.0000029100.82385.58
Abstract
Background— Primary pulmonary hypertension (PPH) is a severe and progressive disease. Without treatment, the median survival is 2.8 years, with survival rates of 68%, 48%, and 34% at 1, 3, and 5 years, respectively. Intravenous epoprostenol was the first Food and Drug Administration–approved therapy for PPH. The long-term impact that epoprostenol has made on PPH remains to be defined. Methods and Results— One hundred sixty-two consecutive patients diagnosed with PPH and treated with epoprostenol were followed for a mean of 36.3 months (median, 31 months). Data including functional class, exercise tolerance, and hemodynamics were recorded in a customized database. Vital status was verified in each patient. Observed survival with epoprostenol therapy at 1, 2, and 3 years was 87.8%, 76.3%, and 62.8% and was significantly greater than the expected survival of 58.9%, 46.3%, and 35.4% based on historical data. Baseline predictors of survival included exercise tolerance, functional class, right atrial pressure, and vasodilator response to adenosine. Predictors of survival after the first year of therapy included functional class and improvement in exercise tolerance, cardiac index, and mean pulmonary artery pressure. Conclusions— Intravenous epoprostenol improves long-term survival in PPH.Keywords
This publication has 8 references indexed in Scilit:
- Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary ArteryAmerican Journal of Respiratory Cell and Molecular Biology, 2002
- The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertensionJournal of the American College of Cardiology, 1999
- A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart FailureThe New England Journal of Medicine, 1998
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionThe New England Journal of Medicine, 1998
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionThe New England Journal of Medicine, 1996
- Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart FailureThe New England Journal of Medicine, 1993
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991
- Primary Pulmonary HypertensionAnnals of Internal Medicine, 1987